Stock data
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM)
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) reported revenue of US$0.09M and net income of -US$33.89M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.09M | — | -US$36.25M | -US$33.89M | — |
| 2024 | — | — | -US$42.12M | -US$38.24M | — |
| 2023 | US$0.08M | — | -US$51.92M | -US$48.82M | — |
| 2022 | US$1.03M | — | -US$34.10M | -US$33.02M | — |
| 2021 | US$1.14M | — | -US$24.96M | -US$24.77M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$35.00M | US$27.90M | — |
| 2026-03-31 | — | -US$5.52M | — |
| 2025-12-31 | — | -US$5.94M | — |
| 2025-09-30 | US$0.09M | -US$5.13M | — |
| 2025-06-30 | — | -US$6.88M | — |
| 2025-03-31 | — | -US$15.94M | — |
| 2024-12-31 | — | -US$6.65M | — |
| 2024-09-30 | — | -US$11.57M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.